Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV
- PMID: 2548535
- DOI: 10.1097/00002030-198905000-00004
Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV
Abstract
To define the target antigens for antibody-dependent cellular cytotoxicity (ADCC), assays were performed using affinity-purified human immunoglobulin (Ig) or polyclonal rabbit sera directed against specific proteins of HIV. ADCC was not found using affinity-purified anti-core (p25) human Ig or sera obtained from rabbits hyper-immunized with recombinant p25. However, when affinity-purified human Ig or rabbit antisera specific for the envelope glycoproteins, gp120 or gp41, were used in ADCC assays, killing of HIV-infected cells was observed. These results indicate that antibodies in the infected individual that mediate ADCC are directed against both the gp120 and gp41 HIV envelope proteins and not against the viral core protein.
Similar articles
-
Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera.J Virol. 1989 Feb;63(2):584-90. doi: 10.1128/JVI.63.2.584-590.1989. J Virol. 1989. PMID: 2536094 Free PMC article.
-
Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope in sera from different stages of HIV infection.AIDS Res Hum Retroviruses. 1989 Feb;5(1):33-9. doi: 10.1089/aid.1989.5.33. AIDS Res Hum Retroviruses. 1989. PMID: 2541748
-
Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC.AIDS Res Hum Retroviruses. 1987;3(4):409-22. doi: 10.1089/aid.1987.3.409. AIDS Res Hum Retroviruses. 1987. PMID: 2833917
-
Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection.Viral Immunol. 1991 Winter;4(4):215-23. doi: 10.1089/vim.1991.4.215. Viral Immunol. 1991. PMID: 1726398
-
HIV antibodies for treatment of HIV infection.Immunol Rev. 2017 Jan;275(1):313-323. doi: 10.1111/imr.12506. Immunol Rev. 2017. PMID: 28133794 Free PMC article. Review.
Cited by
-
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.J Virol. 2001 Jan;75(2):645-53. doi: 10.1128/JVI.75.2.645-653.2001. J Virol. 2001. PMID: 11134278 Free PMC article.
-
Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection.Clin Diagn Lab Immunol. 1999 Sep;6(5):718-24. doi: 10.1128/CDLI.6.5.718-724.1999. Clin Diagn Lab Immunol. 1999. PMID: 10473524 Free PMC article.
-
Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort.Clin Exp Immunol. 1990 Jul;81(1):5-10. doi: 10.1111/j.1365-2249.1990.tb05283.x. Clin Exp Immunol. 1990. PMID: 2379323 Free PMC article.
-
Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.Vaccine. 2007 Jun 21;25(26):4949-59. doi: 10.1016/j.vaccine.2007.01.118. Epub 2007 Feb 26. Vaccine. 2007. PMID: 17350736 Free PMC article.
-
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.J Immunol. 2009 Mar 15;182(6):3718-27. doi: 10.4049/jimmunol.0803115. J Immunol. 2009. PMID: 19265150 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources